In this study, researchers will explore experiences of mentorship and transition to practice for newly graduated nurses in Alberta and British Columbia. The aim of the study is to better understand these experiences to develop helpful and meaningful ways of supporting the transition to registered nurse practice.

The University of Calgary, Division of Rheumatology is developing a Registry of patients with Vasculitis in the Southern Alberta Region. What will the registry be used for? • Collect information on your specific disease course, treatments and outcomes. • To establish a blood bank to examine the profiles of patients with vasculitis to determine their clinical features and response to therapy. • Notification of opportunities to participate in rheumatology research studies in the Calgary region. • Notification of educational activities (seminars, patient newsletters) in the Calgary region. Taking part in this study involves? For this study, you will meet with Dr. Fifi-Mah or Dr Garner, rheumatologists at South health Campus, once a year. At your annual visit, your medical history will be reviewed and you will have a physical exam performed. You will be asked to complete a questionnaire about your symptoms and quality of life. You will also have a blood test done. We expect each of these study visits to last up to 30 minutes in duration. We would arrange the study visits when you are due to attend the hospital for your scheduled clinical appointments so you will not have any additional hospital visits. What about the Confidentiality Your participation in this study is completely voluntary. Please note that your non-participation will not affect the quality of care you’ll receive from your health care provider. All communications will remain confidential between you and the research team.

Many individuals with neurodevelopmental disorders have behaviours of concern, like aggression or self-injury. These behaviours can cause harm to the child themselves or others. These behaviours are hard to treat because we don't understand them very well. Researchers and doctors need a good way to measure behaviours of concern so they can figure out what helps. To help, we are developing a new scale, the Behaviours of Concern Assessment Instrument (BoCAI). We need caregivers to use the BoCAI and provide feedback to help us make the BoCAI better.

A randomized cross-over study will be conducted. Eligible participants will complete a familiarity session (if needed) where the child will be acquainted with the Levity, followed by one or two sessions using the participant’s current walking aid and the Levity, in random order. Physical activity intensity will be measured by step count using an ankle worn accelerometer and heart rate using a chest-worn monitor. Differences in physical activity intensity (steps and mean heart rate over a standardized 6-minute walking test during the sessions) will be compared. Additionally, parents/caregivers will be asked to rate their perception of their child's level of exertion while using each device.

This study is being done to see if small skin samples can help doctors tell the difference between Parkinson’s disease and other similar movement disorders, like multiple system atrophy (MSA). These conditions can be hard to tell apart using normal tests. We are also studying people with isolated REM sleep behavior disorder (iRBD). This is a sleep condition where people act out their dreams because their muscles don’t relax during REM sleep. iRBD is important because some people with this condition may develop Parkinson’s disease or another related disorder later on. The purpose of this research study is to look at tiny skin samples for a protein called alpha-synuclein. This protein may show up in different patterns in Parkinson’s disease, MSA, and iRBD. By studying these patterns, we hope to help doctors make earlier and more accurate diagnoses in the future.

This study is recruiting first-degree relatives (biological parents, children, and siblings) of people with pulmonary fibrosis (PF) to help design a future research program that will screen family members for PF. We know that first degree family members of people affected by PF are at 8-9x higher risk of developing it than the general population. For this reason, we want to develop a research program to screen family members. Researchers would like to hear your perspectives on what matters to you as a relative of someone affected by pulmonary fibrosis, and as someone potentially at-risk of developing it one day. Your insights will help us design a future research program that will screen at-risk individuals for this type of lung disease, to help us understand why some people develop PF and others don’t. Qualifying participants are invited to complete a 10–15-minute online survey (via the link below), which will ask about: • Any concerns about developing pulmonary fibrosis • What information you would want from being screened for pulmonary fibrosis • What forms of screening, testing, and long-term monitoring you may be willing to undergo (e.g. blood test, CT scan, pulmonary function test) • How you would prefer to receive screening results • Barriers and challenges you face that may prevent you from participating in a pulmonary fibrosis screening program At the end of the survey, you may choose to share more by taking part in a one-time Zoom interview (30-45 minutes). The interview will be recorded for analysis purposes. If you would like to participate in an interview but not the survey, you may contact the study team directly through the contact details on this page. Please note that participation in these surveys/interviews does not guarantee eligibility for participation in a future pulmonary fibrosis screening program.

The goal of this study is to learn more about the genetics of neurological conditions. We are collecting DNA and RNA samples from blood for use in experimental gene sequencing methods. We are recruiting individuals with neurologic conditions, as well as control participants.

Survey link - https://redcap.link/NursesAlberta This study is an online survey (and optional small group discussion) about nurses (RN, RNNP, RPN LPN)’ interest in working in private practice in Alberta, such as in Home Care. We want to learn how many nurses are interested in this kind of work, what would motivate them, and what gets in the way. We will ask about things like training, rules and paperwork, insurance, costs to get started, finding clients, and how nurses would get paid for services. At the end of the survey, you can choose to share your contact information if you want to join a focus group. What you share will help identify practical supports that could make it easier for nurses to offer home-based care through private practice.

This study is for patients with allergic asthma. Asthma can cause the airways of the lungs to narrow (airways are the tubes which carry air into the lungs). This can cause wheezing, shortness of breath, chest tightness and/or cough. This airway narrowing is often due to chronic inflammation in the lungs. The investigational study drug (known as ARO-RAGE) is being developed to treat asthmatics by reducing the amount of a protein in the lung (called Receptor for Advanced Glycation End-products, or RAGE). The RAGE protein may cause inflammation in the lung airways, so it is possible that ARO-RAGE will decrease this inflammation. This may result in better airflow, improved symptoms, and fewer asthma flare-ups (exacerbations). It is also possible that you may receive no benefit and it may not result in these improved symptoms.

This study is open to adults aged 40 and older who have idiopathic pulmonary fibrosis (IPF). The purpose of the study is to determine if nintedanib solution for inhalation (AP02) is safe, tolerable, and effective for people with IPF. The study involves 7 visits over a period of up to 16 weeks. There will be a screening period of up to 14 days, a 12-week treatment period, and a 2-week follow-up period. Participants will be randomly assigned to 1 of 3 treatment arms: Group 1: study drug AP02 4mg (high dose) inhaled twice a day by mouth Group 2: study drug AP02 2mg (low dose) inhaled twice a day by mouth Group 3: placebo inhaled twice a day by mouth There is a 63% change of receiving AP02 and a 37% chance of receiving placebo. The placebo will look like AP02 but will contain no active medicine.